Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients.
Antibody Formation
/ immunology
Antigens, Neoplasm
/ immunology
Biomarkers, Tumor
/ immunology
Female
Head and Neck Neoplasms
/ immunology
Humans
Male
Melanoma-Specific Antigens
/ immunology
Neoplasm Proteins
/ immunology
Neoplasm Staging
Papillomaviridae
/ immunology
Papillomavirus Infections
/ complications
Prognosis
Proto-Oncogene Proteins c-myc
/ immunology
RNA-Binding Proteins
/ immunology
Squamous Cell Carcinoma of Head and Neck
/ immunology
Survival Rate
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 12 2019
15 12 2019
Historique:
received:
09
05
2019
revised:
27
06
2019
accepted:
20
08
2019
pubmed:
25
8
2019
medline:
27
10
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
The identification of high-risk patients within human papillomavirus (HPV)-positive and -negative head and neck squamous cell carcinoma (HNSCC) is needed for improved treatment and surveillance strategies. In this study, we set out to discover antibody responses (AR) with prognostic impact in HNSCC stratified by HPV status. A fluorescent bead-based multiplex serology assay on 29 cancer antigens (16 cancer-testis antigens, 5 cancer-retina antigens, and 8 oncogenes) and 29 HPV antigens was performed in samples of 362 patients with HNSCC from five independent cohorts (153 HPV positive, 209 HPV negative). A multivariable Cox proportional hazard model with bootstrapping (M = 1000) was used for validation of prognostic antibody responses. Antibody response to any of the cancer antigens was found in 257 of 362 patients (71%). In HPV-negative patients, antibody responses to c-myc, MAGE-A1, -A4, and Rhodopsin E2 (combined as AR We identified antibody responses to cancer antigens that associate with a dismal prognosis in patients with HNSCC beyond HPV-positive status. AR
Identifiants
pubmed: 31444248
pii: 1078-0432.CCR-19-1490
doi: 10.1158/1078-0432.CCR-19-1490
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
IGF2BP1 protein, human
0
MAGEA1 protein, human
0
MAGEA4 protein, human
0
MYC protein, human
0
Melanoma-Specific Antigens
0
Neoplasm Proteins
0
Proto-Oncogene Proteins c-myc
0
RNA-Binding Proteins
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7405-7412Informations de copyright
©2019 American Association for Cancer Research.